Seres Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview

Seres Therapeutics

05/05/2025 13:32

Seres Therapeutics Inc MCRB.OQ MCRB.O is expected to show a rise in quarterly revenue when it reports  results on May 7 for the period ending March 31 2025

The Cambridge Massachusetts-based  company is expected to report revenue of $10 million, according to the mean estimate from 5 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Seres Therapeutics Inc is for a loss of 54 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Seres Therapeutics Inc is $73.70‚Äč, above‚Äč its last closing price of $9.63. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-3.75
-3.94
-2.00
Beat
49.2
Sep. 30 2024
-4.88
-4.91
-7.60
Missed
-54.8
Jun. 30 2024
-5.46
-5.48
-4.40
Beat
19.7‚Äč
Mar. 31 2024
-6.95
-6.82
-5.40
Beat
20.8
‚Äč‚ÄčDec. 31 2023
-7.95
-9.94
-6.40
Beat
35.6
Sep. 30 2023
-9.87
-10.03
-7.40
Beat
26.2‚Äč
Jun. 30 2023
10.58
10.68
7.20
Missed
-32.6
Mar. 31 2023
-11.23
-10.98
-11.40
Missed
-3.8

This summary was machine generated May 5 at 12:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)